Study details
Enrolling now
Convalescent Plasma as a Possible Treatment for COVID-19
University of Illinois at Chicago
NCT IDNCT04442191ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
50
Study length
about 1 year
Ages
40+
Locations
1 site in IL
Why this study is shown
Matches covid 19Actively enrollingPHASE2
What this study is about
Researchers are testing if convalescent plasma, which contains antibodies from people who have recovered from COVID-19, can help people who are currently ill with the virus. The trial will compare this treatment to a placebo (an inactive substance) and assess its safety. It will last for 365 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Convalescent plasma
- 2.Receive Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: C-reactive Protein (CRP)
Body systems
Infectious